Please login to the form below

Not currently logged in

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

Gilead Sciences BuildingJanssen and Gilead Sciences have extended an existing agreement to develop a single-tablet treatment for HIV.

The two companies – both of which have made major developments in infectious diseases in the past year – have completed several phase I and phase II trials involving a single, once-daily drug for HIV having originally agreed to work together in 2011.

The treatment in development combines Janssen's Prezista (darunavir) with Gilead's Tybost (cobicistat), generic emtricitabine and tenofovir alafenamide, an investigational prodrug in development by Gilead.

Now the two companies have agreed to take the partnership further with the amended deal seeing Janssen responsible all further clinical development and all manufacturing, registration, distribution and commercialisation of the combination drug.

Paul Stoffels, chief scientific officer and chairman of pharmaceuticals at Johnson & Johnson, said: “We are proud to be extending our collaboration and leading the development of this darunavir-based single tablet regimen. Our ultimate goal is to offer new treatment options for people living with HIV.”

If successfully developed and approved, the treatment would be the first protease inhibitor-based STR available for people with HIV.

Janssen and Gilead have also expanded another agreement concerning Complera, a combination of rilpivirine, tenofovir disoproxil fumarate and emtricitabine that is marketed as Eviplera in the EU. The alterations to the agreement will mean Gilead's tenofovir alafenamide will replace tenofovir disoproxil fumarate within Eviplera.

In clinical trials, tenofovir alafenamide has proved to have a better renal and bone safety profile than TDF.

Article by
Kirstie Pickering

6th January 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...